A novel D2-dopaminergic and α2-adrenoceptor receptor agonist induces substantial and prolonged IOP decrease in normotensive rabbits

Journal of Pharmacy and Pharmacology

Volumn 55, Issue 6, 2003, Pages 789-794

  Savolainen, Jouko ^a   Rautio, Jarkko ^a   Razzetti, Roberta ^b   Järvinen, Tomi ^a,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b CHIESI FARMACEUTICI S P A   (Italy)

^c Finncovery Ltd   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIHYDROXY 2 METHYLAMINOTETRALIN; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRIMONIDINE; CHF 1800; CHF 1810; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DRUG METABOLITE; NOLOMIROLE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG INDICATION; DRUG MIXTURE; DRUG RECEPTOR BINDING; DRUG SOLUTION; DRUG STRUCTURE; ENANTIOMER; EYE IRRITATION; EYELID CLOSURE; FEMALE; GLAUCOMA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; NONHUMAN; RABBIT; STEREOCHEMISTRY;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTERS; INTRAOCULAR PRESSURE; NAPHTHALENES; RABBITS; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE D2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDRONAPHTHALENES;

EID: 0037530381     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/002235703765951393     Document Type: Article

References (25)

1. Burke, J.A., Potter, D.E. (1986) Ocular effects of a relatively selective a2 agonist (UK-14, 304 18) in cats, rabbits and monkeys. Curr. Eye Res. 5: 665-676
2. Burke, J., Schwartz, M. (1996) Preclinical evaluation of Brimonidine. Surv. Ophthalmol. 41 (Suppl. 1): 9-18
3. Carabaza, A., Cabre, F., Rotllan, E., Gomez, M., Gutierrez, M., Garcia, M. L., Mauleon, D. (1996) Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs. J. Clin. Pharmacol. 36: 505-512
4. Davies, N. M. (2000) Biopharmaceutical considerations in topical ocular drug delivery. Clin. Exp. Pharmacol. Phys. 27: 558-562
5. Enyedi, L. B., Freedman, S. F. (2001) Safety and efficacy of brimonidine in children with glaucoma. J. AAPOS 5: 281-284
6. Greaves, J. L., Olejnik, O., Wilson, C. G. (1992) Polymers and the precorneal tear film. S.T.P. Pharma Sci. 2: 13-33
7. Greenfield, D. S., Liebmann, J. M.,Ritch, R. (1997) Brimonidine: A new alpha2-adrenoreceptor agonist for glaucoma treatment. J. Glaucoma 6: 250-258
8. Harrison, R., Kaufmann, C. S. (1977) Clonidine, effects of a topically administered solution on intraocular pressure and blood pressure in open-angle glaucoma. Arch. Ophthalmol. 95: 1368-1373
9. Hongmei, Y., Lewander T. (1999) Differential tissue distribution of the enantiomers of racemic pindolol in the rat. Eur. Neuropsychopharmacol. 10: 59-62
10. Karnezis, T. A., Murphy, M. B. (1988) Dopamine receptors and intraocular pressure. Trends Pharmacol. Sci. 9: 389-390
11. Kaufman, P. L., Mittag, T. W. (1994) Medical therapy of glaucoma. In: Podos, S. M., Yanoff, M. (eds) Textbook of Ophthalmology. Vol 7, Mosby, London, pp 7-30
12. Kroemer, H. K., Fromm, M. F., Eichelbaum, M. (1996) Stereoselectivity in drug metabolism and action: Effects of enzyme inhibition and induction. Ther. Drug Monit. 18: 388-392
13. Le Bourlais, C. A., Treupel-Acar, L., Rhodes, C. T., Sado, P. A., Leverge, R. (1995) New ophthalmic drug delivery systems. Drug Dev. Ind. Pharm. 21: 19-59
14. Lee, D. A., Gornbein, J., Abrams, C. (2000) The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: A post hoc analysis of an open-label community trial. J. Ocul. Pharmacol. Ther. 16: 3-18
15. McMurray, J., Pfeffer, M. A. (2002) New therapeutic options in congestive heart failure: Part 1. Circulation 105: 2099-2106
16. Ogidigben, M., Chu, T.-C., Potter, D. E. (1993) Ocular hypotensive action of dopaminergic (DA2) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine. J. Pharmacol. Exp. Ther. 267: 822-827
17. Pastore, F., Bergamaschi, M., Razzetti, R., Caruso, P., Giossi, M., Bongrani, S. (2000) Receptor profile of a potent and selective DA2/alpha2 agonist. Eur. J. Heart Failure (Suppl. 2): 95
18. Pastore, F., Razzetti, R., Riunno, M., Bergamaschi, M., Caruso, P., Giossi, M., Civelli, M., Bongrani, S. (2001) Pharmacological characterisation of the enantiomers of nolomirole, a selective D2-dopaminergic and a2-adrenergic receptors agonist. Pharmacol. Res. 43: (Suppl. A): 107
19. Prunte, C., Nuttli, I., Markstein, R., Kohler, C. (1997) Effects of D-1 and D-2 receptors on intraocular pressure in conscious rabbits. J. Neural Transm. 104: 111-123
20. Razzetti, R., Pastore, F., Riunno, M., Bergamaschi, M., Caruso, P., Rondelli, I., Bongrani, S. (2000) Hemodynamic and neurohormones release inhibiting effects of a DA2/alpha2 agonist. Eur. J. Heart Failure (Suppl. 2): 94
21. Surgue, M. F. (1997) New approaches to antiglaucoma therapy. J. Med. Chem. 40: 2793-2809
22. Tarjányi, Z., Kalász, H., Szebeni, G., Hollósi, I., Báthori, M., Fürst, S. (1998) Gas-chromatographic study on the stereoselectivity of deprenyl metabolism. J. Pharm. Biomed. Anal. 17: 725-731
23. Tjeerdsma, G., Van Wijk, L. M., Molhoek, G. P., Boomsma, F., Haaksma, J., Van Veldhuisen, D. J. (2001) Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. Cardiovasc. Drugs Ther. 15: 139-145
24. Vartiainen, J., MacDonald, E., Urtti, A., Rouhiainen, H., Virtanen, R. (1992) Dexmedetomidine-induced ocular hypotension in rabbits with normal or elevated intraocular pressures. Invest. Ophthalmol. Vis. Sci. 33: 2019-2023
25. Wallace, L. M., Alward, M. D. (1998) Medical management of glaucoma. N. Engl. J. Med. 339: 1298-1307